(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 December 2014 (04.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/193716 A2

(51) International Patent Classification:
C12N 15/864 (2006.01)

(21) International Application Number:
PCT/US2014/039015

(22) International Filing Date:
21 May 2014 (21.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13/899,481 21 May 2013 (21.05.2013) US

(71) Applicant: **UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.** [—/US]; 223 Grinter Hall, Gainesville, Florida 32611 (US).

(72) Inventors: **SRIVASTAVA, Arun**; 3823 SW 92nd Drive, Gainesville, Florida 32608 (US). **ZHONG, Li**; 404 Sargent Road, Boxborough, Massachusetts 01719 (US). **ZOLOTUKHIN, Sergei**; 1122 Sw 96, Gainesville, Florida 32607 (US). **ASLANIDI, George V.**; 2411 NW 69th Terrace, Gainesville, Florida 32626 (US). **AGBANDJE-MCKENNA, Mavis**; 10202 SW 17th Place, Gainesville, Florida 32607 (US). **VAN VLIET, Kim M.**; 8124 SW 57th Place, Gainesville, Florida 32608 (US).


(74) Agents: **MOORE, Mark** et al.; Haynes and Boone, LLP, 2323 Victory Avenue, Suite 700, Dallas, Texas 75219 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER

FIG. 9A



(57) Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.

WO 2014/193716 A2

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with information concerning one or more priority claims considered void (Rule 26bis.2(d))*

— *with sequence listing part of description (Rule 5.2(a))*